Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

A phase I study to establish the safety and tolerability of ARC1905 (Anti-C5 Aptamer) in subjects with dry age-related macular degeneration
31/12/2011

Foto53_4

The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injections in subjects with geographic atrophy secondary to dry age-related macular degeneration(AMD). Patients were assigned in an alternating fashion to one of two dose levels of ARC1905: 0.3 or 1 mg/eye. Patients were treated with 3 initial intravitreal injections of ARC1905 at Day 0,Week 4,Week 8, and a followup visit at Week 16. They then received 2 subsequent injections at Week 24 and Week 36, with a final follow-up visit at Week 48. There was a maximum of 5 ARC1905 injections.

RESULTS: Pending analysis data. No safety concerns in this phase I intravitreal use for the first time of aptamer anti C5 for geographic atrophy.

Injections intravitréennesDMLA « sèche » ou atrophiqueDMLA exsudative ou humideRétinographieAutofluorescenceMicropérimétrieAngiographie en fluorescenceTomographie par cohérence optique

Author

Dr Jordi Monés, médecin, titulaire d’un doctorat
Inscrit à l'ordre des médecins de Barcelone, sous le numéro 22838
Directeur
Docteur en médecine et chirurgie
Spécialiste en ophtalmologie
Spécialiste de la rétine, de la macula et du vitré

Last modified: 14 November, 2019 - 16:33